Art. 5 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

Submission of an application

In forcesince 16 Apr 2014cited 8×
1.

In order to obtain an authorisation, the sponsor shall submit an application dossier to the intended Member States concerned through the portal referred to in Article 80 (the ‘EU portal’).

The sponsor shall propose one of the Member States concerned as reporting Member State.

If a Member State concerned other than the proposed reporting Member State is willing to be the reporting Member State or where the proposed reporting Member State does not wish to be the reporting Member State, this shall be notified through the EU portal to all Member States concerned not later than three days after the application dossier is submitted.

If only one Member State concerned is willing to be the reporting Member State or if the clinical trial involves only one Member State, that Member State shall be the reporting Member State.

If there is no Member State concerned willing to be the reporting Member State or if there is more than one Member State concerned willing to be the reporting Member State, the reporting Member State shall be selected by agreement among the Member States concerned taking into account the recommendations referred to in point (c) of Article 85(2).

If there is no agreement among the Member States concerned, the proposed reporting Member State shall be the reporting Member State.

The reporting Member State shall notify the sponsor and the other Member States concerned that it is the reporting Member State, through the EU portal, within six days from the submission of the application dossier.

2.

The sponsor shall, when applying for a low-intervention clinical trial, where the investigational medicinal product is not used in accordance with the terms of the marketing authorisation but the use of that product is evidence-based and supported by published scientific evidence on the safety and efficacy of that product, propose one of the Member States concerned where the use is evidence-based, as reporting Member State.

3.

Within 10 days from the submission of the application dossier, the reporting Member State shall validate the application taking into account considerations expressed by the other Member States concerned and notify the sponsor, through the EU portal, of the following:

(a)

whether the clinical trial applied for falls within the scope of this Regulation;

(b)

whether the application dossier is complete in accordance with Annex I;

Member States concerned may communicate to the reporting Member State any considerations relevant to the validation of the application within seven days from the submission of the application dossier.

4.

Where the reporting Member State has not notified the sponsor within the period referred to in the first subparagraph of paragraph 3, the clinical trial applied for shall be deemed to fall within the scope of this Regulation and the application dossier shall be considered complete.

5.

Where the reporting Member State, taking into account considerations expressed by the other Member States concerned, finds that the application dossier is not complete, or that the clinical trial applied for does not fall within the scope of this Regulation, it shall inform the sponsor thereof through the EU portal and shall set a maximum of 10 days for the sponsor to comment on the application or to complete the application dossier through the EU portal.

Within five days from receipt of the comments or the completed application dossier, the reporting Member State shall notify the sponsor as to whether or not the application complies with the requirements set out in points (a) and (b) of the first subparagraph of paragraph 3.

Where the reporting Member State has not notified the sponsor within the period referred to in the second subparagraph, the clinical trial applied for shall be deemed to fall within the scope of this Regulation and the application dossier shall be considered complete.

Where the sponsor has not provided comments or completed the application dossier within the period referred to in the first subparagraph, the application shall be deemed to have lapsed in all Member States concerned.

6.

For the purposes of this Chapter, the date on which the sponsor is notified in accordance with paragraph 3 or 5 shall be the validation date of the application. Where the sponsor is not notified, the validation date shall be the last day of the respective periods referred to in paragraphs 3 and 5.

  • Gesetz über den Verkehr mit Arzneimitteln40Law

    … 536/2014 genehmigt hat. (2) Der nach Artikel 5 Absatz 1 der Verordnung (EU) Nr. 536/2014 zu stellende Antrag auf Genehmigung einer klinischen Prüfung ist über das EU-Portal in deutscher oder englischer Sprache einzureichen. Die …

  • Code de la santé publiquer1124-2Law

    Après le dépôt de la demande d'évaluation d'essai clinique définie au 1 de l'article 5 du règlement (UE) n° 536/2014 du Parlement européen et du Conseil du 16 avril 2004, un comité de protection des personnes est désigné selon …

  • KPBV567Law

    … Im Fall einer Mitteilung an den Sponsor nach Artikel 5 Absatz 5 Unterabsatz 1 der Verordnung (EU) Nr. 536/2014 gibt die zuständige Ethik-Kommission ihre Stellungnahme nach § 40 Absatz 3 Satz 2 des Arzneimittelgesetzes oder ihre Bewertung …

  • Regulation (EU) 2022/20135Law

    … на препоръки за докладващите държави членки, посочени в член 5 от Регламент (ЕС) № 536/2014, и за засегнатите държави членки, насочени …

  • Order of the President of the General Court of 12 December 2025. Merck Europe BV v European Commission.Decision

    In circumstances such as those of the present case, under Article 5 of Regulation No 536/2014, applications for clinical trials are to be submitted to the competent authorities of the Member States. In addition, under the first paragraph …

    12 Dec 2025 · 62025TO0637

  • Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision

    Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …

    3 Jul 2025 · 62024CO0139

  • Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision

    Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …

    3 Jul 2025 · 62024CO0148

  • KPBV567Law